<DOC>
	<DOCNO>NCT00085787</DOCNO>
	<brief_summary>This Phase 1 study patient advance solid tumor receive investigational study drug ARRY-142886 . This study 2 part . In first part , patient receive increase dos study drug order achieve high dose study drug possible cause unacceptable side effect . Approximately 25 patient US enrol Part 1 ( Completed ) . In second part study , patient receive best dose study drug , determine first part study , follow see side effect study drug cause effectiveness study drug , , treat cancer . Approximately 35 patient US enrol Part 2 ( Completed ) .</brief_summary>
	<brief_title>A Study ARRY-142886 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 2 ) : Histopathologically cytologically confirm solid tumor refractory standard therapy , standard therapy exist , Investigator feel active therapy require duration study . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 . Estimated life expectancy great equal 3 month . Patient must tumor accessible biopsy must consent paired tumor biopsy normal skin biopsy take pre postdose study drug . Additional criterion exist . Key Exclusion Criteria ( Part 2 ) : Uncontrolled symptomatic brain metastasis . Use investigational drug device within 30 day prior first dose study drug . Major surgery within 30 day prior study start . Radiotherapy chemotherapy within 21 day prior study start ( include palliative radiotherapy focal site ) . Pregnancy lactation . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or hepatitis C. Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>